Literature DB >> 3366159

The efficacy and tolerance to three doses of diltiazem in elderly patients with stable angina.

R L Logan1.   

Abstract

Twelve patients aged 71-82 years with chronic stable angina were treated with the calcium antagonist diltiazem in three successive doses, 180, 270 and 360 mg/day each over two weeks. Exercise tolerance increased and trinitrin consumption fell on the first dose but showed no further change on the higher doses. Heart rates at rest and on maximal treadmill exercise were significantly reduced on the highest dose only. Adverse effects were experienced by 1, 3 and 8 subjects respectively on the three doses. The most frequent was constipation which was of sufficient severity to cause three to withdraw from treatment. It is concluded that, of the three doses studied, the optimal daily dose of diltiazem for elderly patients is 180 mg/day.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3366159     DOI: 10.1007/bf00542487

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Multiple-lead exercise electrocardiography. Experience in 107 normal subjects and 67 patients with angina pectoris, and comparison with coronary cinearteriography in 84 patients.

Authors:  R E Mason; I Likar; R O Biern; R S Ross
Journal:  Circulation       Date:  1967-10       Impact factor: 29.690

2.  Studies on a new 1, 5-benzothiazepine derivative (CRD-401). II. Vasodilator actions.

Authors:  T Nagao; M Sato; H Nakajima; A Kiyomoto
Journal:  Jpn J Pharmacol       Date:  1972-02

3.  The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study.

Authors:  J Hung; I H Lamb; S J Connolly; K R Jutzy; M L Goris; J S Schroeder
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

4.  Long-term monotherapy of angina pectoris with diltiazem.

Authors:  K F Hossack; P E Pool; S C Seagren; B Day; R A Bruce
Journal:  Aust N Z J Med       Date:  1985-04

5.  Comparative effects of three calcium antagonists, diltiazem, verapamil and nifedipine, on the sinoatrial and atrioventricular nodes. Experimental and clinical studies.

Authors:  C Kawai; T Konishi; E Matsuyama; H Okazaki
Journal:  Circulation       Date:  1981-05       Impact factor: 29.690

6.  Improved efficacy of high-dose versus medium- and low-dose diltiazem therapy for chronic stable angina pectoris.

Authors:  M Go; M Hollenberg
Journal:  Am J Cardiol       Date:  1984-03-01       Impact factor: 2.778

7.  Predisposing factors in adverse reactions to drugs.

Authors:  N Hurwitz
Journal:  Br Med J       Date:  1969-03-01

8.  Calcium entry blockers: antihypertensive and natriuretic effects in experimental animals.

Authors:  T Nagao; I Yamaguchi; H Narita; H Nakajima
Journal:  Am J Cardiol       Date:  1985-12-06       Impact factor: 2.778

9.  Superiority of combined diltiazem and propranolol therapy for angina pectoris.

Authors:  W E Strauss; A F Parisi
Journal:  Circulation       Date:  1985-05       Impact factor: 29.690

10.  Comparison of diltiazem and nifedipine for both angina pectoris and systemic hypertension.

Authors:  W H Frishman; S Charlap; J Goldberger; B Kimmel; J Stroh; F Dorsa; L Allen; J Strom
Journal:  Am J Cardiol       Date:  1985-12-06       Impact factor: 2.778

View more
  3 in total

1.  Effect of verapamil on human intestinal transit.

Authors:  B Krevsky; A H Maurer; T Niewiarowski; S Cohen
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 2.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

3.  Antianginal efficacy and safety of controlled-delivery diltiazem QD versus an equivalent dose of immediate-release diltiazem TID.

Authors:  W P Klinke; M Baird; M Juneau; D Waters; W Warnica; Z Lakhani; L Annable; A P Boulet; L Larivière
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.